Evaluation of Reporting of AdVerse Events Associated With AnTicAncer theRapy (AVATAR)

Evaluation of Reporting of AdVerse Events Associated With AnTicAncer theRapy : an Observational and Retrospective Study Using the WHO Pharmacovigilance Database(AVATAR)

Anticancer drugs can lead to various adverse events. This study analyses reports of adverse events for treatment including Anatomical Therapeutic Chemical (ATC) classification L (antineoplastic agents, endocrine therapy, immunostimulants, and immunosuppressants drugs) in the World Health Organization's (WHO) global database of individual safety case reports (VigiBase).

The investigators use VigiBase, the World Health Organization (WHO) database of individual safety case reports, to identify cases of adverse events following treatment with antineoplastic agents, endocrine therapy, immunostimulants or immunosuppressants drugs.

Inclusion Criteria:

• Case reported in the World Health Organization (WHO) database of individual safety case reports at the time of the extraction
• Adverse events reported were including in the MedDRA terms. The research could include the report with SOC, HGLT, HLT, or PT MedDRA terms
• Patients treated with Antineoplastic and immunomodulating agents included in the ATC L.

Exclusion Criteria:

• Chronology not compatible between the drug and the toxicity